Is Benitec Biopharma Ltd ADR (BNTC) overvalued? · $388.7M cap
Benitec Biopharma Ltd ADR (BNTC) is a biotechnology company listed on NASDAQ.
This page asks whether Benitec Biopharma Ltd ADR (BNTC) looks expensive on cached numbers — not a short thesis.
Latest reported BNTC revenue for 2025-09-30 was $0. Net income was -$9.0M. BNTC currently screens at market cap $388.7M.
BNTC currently screens at market cap $388.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BNTC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BNTC stock page for the full model, not this heading.
Not investment advice.